Di Cosimo et al. showed that the pathological complete response rate after anti-HER2 therapies in overweight and obese patients with hormone receptor (HR)-positive, HER2-positive BC included in the neo-ALTTO trial was lower compared to their lean counterparts. This evidence concerns the gene ERBB2 and breast cancer.